Histrelin (BioDeep_00000858474)

   

Volatile Flavor Compounds


代谢物信息卡片


Histrelin

化学式: C66H86N18O12 (1322.6672276)
中文名称: 组氨瑞林
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC2=CN(C=N2)CC3=CC=CC=C3)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8
InChI: InChI=1S/C66H86N18O12/c1-4-70-64(95)55-17-11-25-84(55)65(96)48(16-10-24-71-66(67)68)76-58(89)49(26-38(2)3)77-62(93)53(30-43-34-83(37-74-43)33-40-12-6-5-7-13-40)81-59(90)50(27-39-18-20-44(86)21-19-39)78-63(94)54(35-85)82-60(91)51(28-41-31-72-46-15-9-8-14-45(41)46)79-61(92)52(29-42-32-69-36-73-42)80-57(88)47-22-23-56(87)75-47/h5-9,12-15,18-21,31-32,34,36-38,47-55,72,85-86H,4,10-11,16-17,22-30,33,35H2,1-3H3,(H,69,73)(H,70,95)(H,75,87)(H,76,89)(H,77,93)(H,78,94)(H,79,92)(H,80,88)(H,81,90)(H,82,91)(H4,67,68,71)/t47-,48-,49-,50-,51-,52-,53+,54-,55-/m0/s1

描述信息

L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02A - Hormones and related agents > L02AE - Gonadotropin releasing hormone analogues
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1910 - Gonadotropin-releasing Hormone Analog
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones

同义名列表

2 个代谢物同义名

Histrelin; Histrelin



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Neal Shore, Michael S Cookson, Marc C Gittelman. Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. BJU international. 2012 Jan; 109(2):226-32. doi: 10.1111/j.1464-410x.2011.10370.x. [PMID: 21851539]
  • E Boczek-Leszczyk, B Stempniak, M Juszczak. Vasopressin release from the rat hypothalamo-neurohypophysial system: effects of gonadotrophin-releasing hormone (GnRH), its analogues and melatonin. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2010 Aug; 61(4):459-66. doi: . [PMID: 20814074]
  • Bob Djavan, Peter Schlegel, Georg Salomon, Elisabeth Eckersberger, Helen Sadri, Markus Graefen. Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer. The Canadian journal of urology. 2010 Aug; 17(4):5265-71. doi: NULL. [PMID: 20735905]
  • Emma D Deeks. Histrelin: in advanced prostate cancer. Drugs. 2010 Mar; 70(5):623-30. doi: 10.2165/11204800-000000000-00000. [PMID: 20329807]
  • Marlena Juszczak, Emilia Boczek-Leszczyk. Hypothalamic gonadotropin-releasing hormone receptor activation stimulates oxytocin release from the rat hypothalamo-neurohypophysial system while melatonin inhibits this process. Brain research bulletin. 2010 Jan; 81(1):185-90. doi: 10.1016/j.brainresbull.2009.10.012. [PMID: 19874874]
  • Talia Eldar-Geva, Gad Liberty, Boris Chertin, Alon Fridmans, Amicur Farkas, Ehud J Margalioth, Irving M Spitz. Relationships between FSH, inhibin B, anti-Mullerian hormone, and testosterone during long-term treatment with the GnRH-agonist histrelin in patients with prostate cancer. European journal of endocrinology. 2010 Jan; 162(1):177-81. doi: 10.1530/eje-09-0366. [PMID: 19820037]
  • I M Spitz, B Chertin, A Fridmans, A Farkas, A Belanger, H Hartman, F Labrie. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists. Prostate cancer and prostatic diseases. 2009; 12(1):100-3. doi: 10.1038/pcan.2008.15. [PMID: 18574491]
  • Martin K Dineen, David S Tierney, Petr Kuzma, Helen S Pentikis. An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer. Journal of clinical pharmacology. 2005 Nov; 45(11):1245-9. doi: 10.1177/0091270005281043. [PMID: 16239357]
  • P N Schlegel, P Kuzma, J Frick, A Farkas, A Gomahr, I Spitz, B Chertin, D Mack, A Jungwirth, P King, H Nash, C W Bardin, A Moo-Young. Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin. Urology. 2001 Oct; 58(4):578-82. doi: 10.1016/s0090-4295(01)01293-6. [PMID: 11597543]
  • A P Cheung, J K Lu, R J Chang. Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment. Human reproduction (Oxford, England). 1997 Jun; 12(6):1156-64. doi: 10.1093/humrep/12.6.1156. [PMID: 9221993]
  • A P Cheung, R J Chang. Pituitary responsiveness to gonadotrophin-releasing hormone agonist stimulation: a dose-response comparison of luteinizing hormone/follicle-stimulating hormone secretion in women with polycystic ovary syndrome and normal women. Human reproduction (Oxford, England). 1995 May; 10(5):1054-9. doi: 10.1093/oxfordjournals.humrep.a136093. [PMID: 7657740]
  • M I Cedars, K A Steingold, J H Lu, H J Judd, D R Meldrum. Pituitary function before, during, and after chronic gonadotropin-releasing hormone agonist therapy. Fertility and sterility. 1992 Dec; 58(6):1104-7. doi: 10.1016/s0015-0282(16)55551-4. [PMID: 1459255]
  • J W Gunnet, K T Demarest, D W Hahn, E Ericson, J L McGuire. Effects of a sustained release formulation of the gonadotrophin-releasing hormone agonist histrelin on serum concentrations of gonadotrophins and oestradiol, and ovarian LH/human chorionic gonadotrophin receptor content in the rat. The Journal of endocrinology. 1991 Nov; 131(2):211-8. doi: 10.1677/joe.0.1310211. [PMID: 1744568]
  • K E Anderson, I M Spitz, C W Bardin, A Kappas. A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria. Archives of internal medicine. 1990 Jul; 150(7):1469-74. doi: NULL. [PMID: 2196028]
  • S L Berga, K L Jones, S Kaufmann, S S Yen. Nocturnal melatonin levels are unaltered by ovarian suppression in girls with central precocious puberty. Fertility and sterility. 1989 Dec; 52(6):936-41. doi: 10.1016/s0015-0282(16)53155-0. [PMID: 2512182]
  • K Steingold, D De Ziegler, M Cedars, D R Meldrum, J K Lu, H L Judd, R J Chang. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease. The Journal of clinical endocrinology and metabolism. 1987 Oct; 65(4):773-8. doi: 10.1210/jcem-65-4-773. [PMID: 3116031]
  • A Phillips, D W Hahn, S Klimek, J L McGuire, W F Crowley. Sensitivity differences in reproductive/endocrine organs to chronically administered LHRH agonists in female rats. Life sciences. 1987 Apr; 40(14):1379-89. doi: 10.1016/0024-3205(87)90328-6. [PMID: 3550346]
  • K Sundaram, A Keizer-Zucker, R B Thau, C W Bardin. Reversal of testicular function after prolonged suppression with an LHRH agonist in rhesus monkeys. Journal of andrology. 1987 Mar; 8(2):103-7. doi: 10.1002/j.1939-4640.1987.tb00959.x. [PMID: 3294772]
  • C C Coddington, R L Collins, T H Shawker, R Anderson, D L Loriaux, C A Winkel. Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri. Fertility and sterility. 1986 May; 45(5):624-9. doi: 10.1016/s0015-0282(16)49332-5. [PMID: 3084300]
  • R G Foldesy, M M Vanderhoof, D W Hahn. Lack of correlation between fertility and sperm numbers in male rats treated with histrelin, a potent LHRH agonist. Journal of andrology. 1986 May; 7(3):140-6. doi: 10.1002/j.1939-4640.1986.tb00897.x. [PMID: 3522515]
  • M J Gibson, D S Kohtz. The effects of the GnRH agonist, [(imBzl)-D-His6, Pro9-NEt]-GnRH, on the response to stress in rats. Contraception. 1985 Jan; 31(1):91-9. doi: 10.1016/0010-7824(85)90078-2. [PMID: 2985331]
  • K Sundaram, R B Thau, M Goldstein, D M Phillips, J Rivier, W Vale, C W Bardin. Effect of an LHRH agonist on pituitary and testicular function in rhesus monkeys. Journal of reproduction and fertility. 1984 Nov; 72(2):365-71. doi: 10.1530/jrf.0.0720365. [PMID: 6439862]
  • J W Wilks. Inhibition of folliculogenesis in the monkey following early follicular phase administration of an LRH agonist. Acta endocrinologica. 1984 Aug; 106(4):538-43. doi: 10.1530/acta.0.1060538. [PMID: 6433613]
  • R F Casper, G F Erickson, S S Yen. Studies on the effect of gonadotropin-releasing hormone and its agonist on human luteal steroidogenesis in vitro. Fertility and sterility. 1984 Jul; 42(1):39-43. doi: 10.1016/s0015-0282(16)47955-0. [PMID: 6373386]
  • B R McCreery, P Licht. Effects of gonadectomy and sex steroids on pituitary gonadotrophin release and response to gonadotrophin-releasing hormone (GnRH) agonist in the bullfrog, Rana catesbeiana. General and comparative endocrinology. 1984 May; 54(2):283-96. doi: 10.1016/0016-6480(84)90183-7. [PMID: 6428971]
  • N G Wang, K Sundaram, S Pavlou, J Rivier, W Vale, C W Bardin. Mice are insensitive to the antitesticular effects of luteinizing hormone-releasing hormone agonists. Endocrinology. 1983 Jan; 112(1):331-5. doi: 10.1210/endo-112-1-331. [PMID: 6291919]
  • Y Q Cao, K Sundaram, C W Bardin, J Rivier, W Vale. Direct inhibition of testicular steroidogenesis and gonadotrophin receptor levels by [(imBzl)-D-His6, Pro9-NEt]GnRH and [D-Trp6, Pro9-NEt]GnRH, potent agonists of GnRH. International journal of andrology. 1982 Apr; 5(2):158-70. doi: 10.1111/j.1365-2605.1982.tb00243.x. [PMID: 6286508]